Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example.

v1

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/0BDC643F.svg?ark=w1%2F20260515%2F0BDC643F&value=id)](https://nobleid.org/work/w1/20260515/0BDC643F)

ARK Inflections

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors